Loading...
•
Jun 30, 2021
Lyell Immunopharma Q2 2021 Earnings Report
Lyell Immunopharma reported financial results for the second quarter of 2021 and provided business highlights.
Key Takeaways
Lyell Immunopharma reported a net loss of $62.6 million for the second quarter of 2021. The company's cash, cash equivalents, and marketable securities totaled $974.8 million as of June 30, 2021, including $391.8 million in net proceeds from its initial public offering.
Achieved operational readiness of state-of-the-art LyFE manufacturing facility to support multiple clinical trials
Expanded Board of Directors with industry and medical leaders Otis Brawley, M.D., Elizabeth Nabel, M.D. and Lynn Seely, M.D.
Strengthened balance sheet with net proceeds of $391.8 million from the sale of 25 million shares of common stock in the Company's initial public offering
Cash, cash equivalents and marketable securities were $974.8 million as of June 30, 2021
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...